Mats Bengtsson

Mats Bengtsson

Auto-generated profile, based on publicly available information

Mats Bengtsson

Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in HLA
Verified
Journal Article
Open access
PDF file
CHCarolyn K. Hurley
Carolyn K. Hurley
JKJane Kempenich
Jane Kempenich
KWKim Wadsworth
Kim Wadsworth
JSJürgen Sauter
Jürgen Sauter
JHJan A. Hofmann
Jan A. Hofmann
JDJason Dehn
Jason Dehn
A catalog of common, intermediate and well‐documented (CIWD) HLA‐A, ‐B, ‐C, ‐DRB1, ‐DRB3, ‐DRB4, ‐DRB5, ‐DQB1 and ‐DPB1 alleles has been compiled from over 8 million individuals using data from 20 unrelated hematopoietic stem cell volunteer donor registries. Individuals are divided into seven geographic/ancestral/ethnic groups and data are summarized for each group and for the total population. P (two‐field) and G group assignments are divided into one of four frequency categories: common (≥1 in 10 000), intermediate (≥1 in 100 000), well‐documented (≥5 occurrences) or not‐CIWD. Overall 26% of alleles in IPD‐IMGT/HLA version 3.31.0 at P group resolution fall into the three CIWD categories. The two‐field catalog includes 18% (n = 545) common, 17% (n = 513) intermediate, and 65% (n = 1997) well‐documented alleles. Full‐field allele frequency data are provided but are limited in value by the variations in resolution used by the registries. A recommended CIWD list is based on the most frequent category in the total or any of the seven geographic/ancestral/ethnic groups. Data are also provided so users can compile a catalog specific to the population groups that they serve. Comparisons are made to three previous CWD reports representing more limited population groups. This catalog, CIWD version 3.0.0, is a step closer to the collection of global HLA frequencies and to a clearer view of HLA diversity in the human population as a whole.

19 May 2022 in Blood
Verified
Journal Article
Open access
PDF file
EPEffie W. Petersdorf
Effie W. Petersdorf
MBMats Bengtsson
Mats Bengtsson
MHMary Horowitz
Mary Horowitz
CMCaroline McKallor
Caroline McKallor
SSStephen R. Spellman
Stephen R. Spellman
OTon behalf of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation
on behalf of the International Histocompatibility Working Group in Hematopoietic Cell Transplantation
HLA-DQ heterodimers increase the susceptibility to autoimmune diseases, but their role in hematopoietic cell transplantation is unknown. We tested the hypothesis that outcome after HLA-matched and HLA-DQ–mismatched hematopoietic cell transplantation is influenced by HLA-DQ heterodimers. Heterodimers were defined in 5164 HLA-matched and 520 HLA-DQ–mismatched patients and their transplant donors according to well-established crystallographic criteria. Group 1 (G1) heterodimers are any DQA1*02/03/04/05/06α paired with any DQB1*02/03/04β. Group 2 (G2) heterodimers are DQA1*01α paired with any DQB1*05/06β. Multivariable models identified significantly higher relapse risk in G1G2 and G2G2 compared with G1G1 HLA-matched patients with malignant disease; risk increased with an increasing number of G2 molecules. In HLA-DQ–mismatched transplantation for malignant diseases, matching or mismatching for G2 increased relapse risk. G2 lowered disease-free survival after both HLA-matched and HLA-DQ–mismatched transplantation. A paradigm based on HLA-DQ heterodimers provides a functional definition of the hematopoietic cell transplantation barrier and a means to lower risks for future patients.

16 July 2020 in Blood
Verified
Journal Article
Open access
PDF file
EPEffie W. Petersdorf
Effie W. Petersdorf
PSPhilip Stevenson
Philip Stevenson
MBMats Bengtsson
Mats Bengtsson
DSDianne De Santis
Dianne De Santis
VDValerie Dubois
Valerie Dubois
MCMary Carrington
Mary Carrington
Hematopoietic-cell transplantation (HCT) from HLA-mismatched unrelated donors can cure life-threatening blood disorders but its success is limited by graft-versus-host disease (GVHD). HLA-B leaders encode methionine (M) or threonine (T) at position 2 and give rise to TT, MT or MM genotypes. The dimorphic HLA-B leader informs GVHD risk in HLA-B-mismatched HCT. If the leader influences outcome in other HLA-mismatched transplant settings, the success of HCT could be improved for future patients. We determined leader genotypes for 11872 patients transplanted between 1988 and 2016 from unrelated donors with one HLA-A -B,-C,-DRB1 or -DQB1 mismatch. Multivariate regression methods were used to evaluate risks associated with patient leader genotype according to the mismatched HLA locus and with HLA-A,-B,-C,-DRB1 or -DQB1 mismatching according to patient leader genotype. The impact of the patient leader genotype on acute GVHD and mortality varied across different mismatched HLA loci. Non-relapse mortality was higher among HLA-DQB1-mismatched MM patients compared to HLA-DQB1-mismatched TT patients (hazard ratio 1.35; P = .01). Grades III-IV GVHD risk was higher among HLA-DRB1-mismatched MM or MT patients compared to HLA-DRB1-mismatched TT patients (odds ratio 2.52 and 1.51, respectively). Patients tolerated a single HLA-DQB1 mismatch better than mismatches at other loci. Outcome after HLA-mismatched transplantation depends on the HLA-B leader dimorphism and the mismatched HLA locus. The patient's leader variant provides new information on the limits of HLA mismatching. The success of HLA-mismatched unrelated transplantation might be enhanced through the judicious selection of mismatched donors for a patient's given leader genotype.

27 December 2019 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
ABAnders Brüggemann
Anders Brüggemann
HMHans Mallmin
Hans Mallmin
MBMats Bengtsson
Mats Bengtsson
NHNils P. Hailer
Nils P. Hailer
Background: Tantalum implants have been used in >500,000 orthopaedic patients. Although the risks of metallosis and aseptic lymphocyte-dominated vasculitis-associated lesions (ALVAL) after total hip arthroplasty (THA) are being debated, we are not aware of any studies investigating the liberation of tantalum ions and their potential effects on the immune system. We evaluated whether tantalum concentrations are elevated after THA with acetabular tantalum implants and assessed potential alterations in T-cell subpopulations. Methods: After a mean follow-up of 4 years (range, 0.5 to 8.9 years) of 144 patients who had undergone THA, blood samples were analyzed regarding blood tantalum concentrations, total white blood-cell counts, and lymphocyte subsets in 3 groups of patients: those treated with non-tantalum primary THA (“primary non-tantalum,” n = 30), those treated with primary THA with a tantalum cup (“primary tantalum,” n = 30), and those who underwent revision surgery with a tantalum shell (“revision tantalum,” n = 84). Blood donors served as controls for immunological parameters (n = 59). Correlations between tantalum concentrations and human leukocyte antigen (HLA)-DR+ T cells were calculated, radiographic signs of implant loosening were assessed, and the Harris hip score (HHS) was used to evaluate hip function. Results: The median tantalum concentration was similar to the detection limit both in the primary non-tantalum group (0.05 µg/L, 95% confidence interval [CI] = 0.05 to 0.05 µg/L) and in the primary tantalum group (0.051 µg/L, 95% CI = 0.050 to 0.055 µg/L), and it was 0.091 µg/L (95% CI = 0.083 to 0.112 µg/L) in the revision tantalum group (p < 0.0001 in the group-wise comparison with both primary non-tantalum and primary tantalum). We found a weak negative correlation of higher tantalum concentration with the concentration of HLA-DR+/CD8+ T cells (r = −0.22, 95% CI = −0.35 to −0.05, p = 0.01) but no correlation of tantalum concentration with the concentration of HLA-DR+/CD4+ T cells (r = −0.11, 95% CI = −0.27 to 0.06, p = 0.24). The values for all lymphocyte subgroups were within normal ranges. No implants were deemed loose. The median HHS was good to excellent. Conclusions: Exposure to stable tantalum cups is associated with low blood concentrations of tantalum. Signs of T-cell activation typical of ALVAL seem to be lacking. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

11 November 2013 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
MBM. Bengtsson
M. Bengtsson
JSJ. Street
J. Street
JJJ. Johnson
J. Johnson
CHC. Harvey
C. Harvey
SCS. Corbin
S. Corbin
CDC. Darke
C. Darke

11 March 2026 in HLA
Verified
Journal Article
Open access
PDF file
EAEsteban Arrieta‐Bolaños
Esteban Arrieta‐Bolaños
EBEdouard F. Bonneville
Edouard F. Bonneville
PCPietro Crivello
Pietro Crivello
TGTobias Gedde‐Dahl
Tobias Gedde‐Dahl
RLRégis Peffault de Latour
Régis Peffault de Latour
KFKatharina Fleischhauer
Katharina Fleischhauer
Haematopoietic cell transplantation (HCT) with HLA‐mismatched unrelated donors (MMUD) offers access to curative therapy for patients lacking well‐matched donors. Accumulating evidence suggests that functional matching among allele‐mismatched pairs can significantly influence patient outcomes. Therefore, real‐world data on mismatch frequencies in MMUD‐HCT could provide fundamental information for the assessment of patient risks and donor selection strategies. Here, we analysed HLA matching in 28,376 first unrelated transplants reported to the EBMT Registry with available 6‐locus high‐resolution typing. Mismatches at each locus were quantified and characterised at the allelic, antigenic and functional (antigen‐recognition domain, peptide‐binding motif) levels. 25% of the transplants were performed across one (9/10; n = 6053) or more (< 9/10; n = 1013) high‐resolution mismatches at the five main HLA loci, a proportion that was markedly higher (43.9%) among transplants performed with post‐transplantation cyclophosphamide (PTCy). Median time from diagnosis to transplant was longer for MMUD compared to 10/10 transplants, but this difference decreased over time (14.9 vs. 11.3 months pre‐2011, p = 0.003; 8.1 vs. 7.4 months 2021–2022, p = 0.016). Across transplant eras, single class I mismatches were three times more common than class II mismatches. Conversely, matching for HLA‐DPB1 increased from 15% pre‐2011 to 31% in 2021–2022. The landscapes of allelic mismatches differed markedly between HLA loci. For class II, skewed distributions dominated by frequent combinations result in significantly higher frequencies of functional matching compared to class I in both PTCy and non‐PTCy pairs. Our study constitutes the first large‐scale characterisation of real‐world HLA mismatch frequencies in contemporary unrelated HCT, bearing implications for future clinical outcome studies.